VistaGen Therapeutics share price logo

VistaGen Therapeutics

NASDAQ: VTGN

$0.28

-0.00

(-0.57%)

as on

VistaGen Therapeutics Stock Performance

as on October 3, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $0.28
    $0.30
    downward going graph

    0.36%

    Downside

    6.76%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.20
    $5.14
    downward going graph

    29.54%

    Downside

    1729.18%

    Upside

    downward going graph

VistaGen Therapeutics share price movements today

Previous Close
$0.28
Open
$0.28
Volume
1.4M
Market Cap
$12.5M
Day's Low - High
$0.28 - $0.30
52 Week Low - High
$0.20 - $5.14

VistaGen Therapeutics Historical Returns

1 Month Return
+ 14.13 %
3 Month Return
+ 12.9 %
1 Year Return
-92.3 %
3 Year Return
-92.73 %
5 Year Return
-99.65 %

VistaGen Therapeutics Stock Fundamentals & Key Indicators

Check VistaGen Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$12.5M

EPS (TTM)

-1.7

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.17

Industry PE ratio

-3.02

PEG Ratio

-0.04

EBITDA

-67.3M

Revenue (TTM)

2.5M

Profit Margin

84.57%

Return On Equity TTM

-152.59%

VistaGen Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of VistaGen Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
VistaGen Therapeutics image
VistaGen Therapeutics
Neutral$12.5M-99.65%-0.1784.57%0.00%
Revolution Medicines image
Revolution Medicines
StrongBuy$44.1B609.62%-23.340.00%0.00%
Moderna image
Moderna
Neutral$75.4B-44.29%-24.08-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.5B180.98%30.1986.04%0.00%
Regeneron image
Regeneron
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for VistaGen Therapeutics Stock including INR - Dollar returns

The VistaGen Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

VistaGen Therapeutics investment value today

Current value as on today

₹8,355

Returns

-₹91,645

(-91.65%)

Returns from VistaGen Therapeutics Stock

-₹92,301 (-92.3%)

Dollar Impact

₹656 (+0.66%)

Analyst Recommendation on VistaGen Therapeutics Stock

Based on 2 analysts

HOLD

0.00%

Buy

100.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'HOLD' rating for VistaGen Therapeutics. Average target price of $1

VistaGen Therapeutics Share Price Target

Get share price movements and forecasts by analysts on VistaGen Therapeutics.

What analysts predicted

71.9%UPSIDE

Target Price

$1

Current Price

$0.281

Analyzed by

2 Analysts

High

$1

Target

$1.00

Low

$1

VistaGen Therapeutics target price $1, a slight upside of 71.9% compared to current price of $0.281. According to 2 analysts rating.

Indian Investors' Interest in VistaGen Therapeutics Stock

Investment in VistaGen Therapeutics Shares on INDmoney has grown by 827.27% in the last 30 days, indicating increased investment activity.

Time period: to

Change:827.27% versus previous 30 day period

Search interest for VistaGen Therapeutics Stock has increased by 146% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:146% versus previous 30 day period

VistaGen Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
0
0
0
1
Gross Profit
0
0
0
0
0
0
0
0
0
1
Operating Income
-11
-12
-14
-15
-14
-15
-20
-19
-16
-13
EBITDA
-11
-10
-12
-13
-13
-14
-19
-18
-16
-12
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-9
-10
-12
-14
-13
-15
-19
-18
-16
-13
Income Tax Expense
0
-
0
-
-
-
-
-
0
-
Net Income
-9
-10
-12
-14
-13
-15
-19
-18
-16
-13
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
30.74%
100.00%
37.62%
100.00%
86.65%

VistaGen Therapeutics Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
1
-
-
-
1
1
0
1
0
1
Gross Profit
1
-
-
0
1
1
0
1
0
1
Operating Income
-10
-14
-24
-19
-17
-47
-59
-33
-55
-72
EBITDA
-9
-14
-24
-20
-17
-47
-58
-28
-50
-71
Interest Expense
0
0
0
0
0
-
0
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-10
-14
-24
-20
-17
-47
-59
-29
-51
-69
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-10
-14
-24
-20
-17
-47
-59
-29
-51
-69
Net Profit Margin
100.00%
0.00%
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%

VistaGen Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-9
-10
-12
-14
-13
-15
-19
-18
-16
-13
Operating Cash Flow
-7
-10
-10
-10
-10
-18
-13
-17
-16
-14
Investing Cash Flow
0
-5
-7
0
0
0
0
0
0
-
Financing Cash Flow
0
0
-
1
1
1
27
2
0
0
Change in Cash
-7
-16
-18
-9
-7
-18
13
-15
-16
-13

VistaGen Therapeutics Annual Cash Flow

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
-10
-14
-24
-20
-17
-47
-59
-29
-51
-69
Operating Cash Flow
-7
-9
-14
-15
-12
-45
-49
-25
-42
-66
Investing Cash Flow
0
0
0
-
0
0
0
0
-13
0
Financing Cash Flow
9
16
17
4
114
10
-1
128
3
30
Change in Cash
2
7
2
-11
101
-34
-51
102
-52
-36

Global Institutional Holdings in VistaGen Therapeutics

Check out the Institutions with significant holdings in VistaGen Therapeutics.

Funds
Holdings
VANGUARD INDEX FUNDS
3.55%
Vanguard
3.55%
AdvisorShares
1.22%
Fidelity Concord Street Trust
0.77%
Victory Portfolios III
0.01%
See all

VistaGen Therapeutics News & Key Events

  • img

    Today's Timeline - 24 September

    Thu, 04:46 PM

    -

    VistaGen presents positive exploratory data on fasedienol nasal spray for severe social anxiety at Psych Congress 2026.

Insights on VistaGen Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 6 quarters, -15.0K → 1.47M (in $), with an average increase of 46.0% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, -19.41M → -13.03M (in $), with an average increase of 14.6% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, VTGN stock has moved up by 14.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 659.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 84.3% return, outperforming this stock by 177.0%

About VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
OrganisationVistaGen Therapeutics
Headquarters343 Allerton Avenue, South San Francisco, CA, 94080, US
IndustryBiotechnology
CEOShawn K. Singh

Key Management of VistaGen Therapeutics

Name

Title

Mr. Reid G. Adler Esq., J.D.

Chief Legal Officer

Ms. Elissa Cote

Chief Corporate Development & Strategy Officer

Mr. Shawn K. Singh J.D.

President, CEO & Director

Mr. Nick B. Tressler M.B.A.

CFO & Treasurer

Mr. Joshua S. Prince M.B.A.

Chief Operating Officer

FAQs

What is VistaGen Therapeutics share price today?

VistaGen Therapeutics share price today is $0.28 as on at the close of the market. VistaGen Therapeutics share today touched a day high of $0.30 and a low of $0.28.

What is the 52 week high and 52 week low for VistaGen Therapeutics share?

VistaGen Therapeutics share touched a 52 week high of $5.14 on and a 52 week low of $0.20 on . VistaGen Therapeutics stock price today i.e. is closed at $0.28,which is 94.53% down from its 52 week high and 41.92% up from its 52 week low.

What is VistaGen Therapeutics's market capitalisation today?

VistaGen Therapeutics market capitalisation is $0.00T as on .

How to invest in VistaGen Therapeutics Stock (VTGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for VistaGen Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy VistaGen Therapeutics Stock (VTGN) from India?

Indian investors can start investing in VistaGen Therapeutics (VTGN) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in VistaGen Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on VistaGen Therapeutics share’s latest price of $0.28 as on October 3, 2026 at 8:46 am IST, you will get 35.5872 shares of VistaGen Therapeutics. Learn more about fractional shares .

What are the returns that VistaGen Therapeutics has given to Indian investors in the last 5 years?

VistaGen Therapeutics stock has given -99.65% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?